Safety Assessment of Zigbir®: A Polyherbal Formulation in Sprague-Dawley Rats

Table 3

Haematological findings (mean ± SD) in female rats after 90 days subchronic oral administration of Zigbir®.

Parameters	Control	250 mg/kg	500 mg/kg	1000 mg/kg	Control recovery	1000 mg/kg recovery
Hb (g%)	14.93 ± 0.83	14.79 ± 0.27	15.23 ± 0.79	15.19 ±1.10	16.74 ± 0.68	16.28 ± 0.33
Total RBC (×10^6/𝜇L)	6.82 ± 0.94	7.63* ± 0.30	7.09 ± 0.31	6.99 ± 0.68	8.05 ± 0.49	7.58 ± 0.38
Rt (%)	1.61 ± 0.42	1.55 ± 0.40	1.80 ± 0.69	1.68 ± 0.44	1.60 ± 0.37	1.68 ± 0.26
HCT (%)	36.38 ± 3.25	39.78** ± 0.85	39.89** ± 1.95	38.98* ± 2.69	46.04 ± 1.51	44.10^# ± 0.97
MCV (𝜇m^3)	53.61 ± 2.83	52.18 ± 1.46	56.27* ± 1.52	55.97 ± 2.90	57.28 ± 2.96	58.24 ± 2.20
MCH (pg)	22.11 ± 1.67	19.39** ± 0.63	21.48 ± 0.63	21.83 ± 1.02	20.88 ± 1.42	21.52 ± 0.89
MCHC (%)	41.22 ± 1.81	37.17** ± 0.62	38.16** ± 0.31	39.00** ± 0.33	36.38 ± 0.73	36.94 ± 0.47
Platelets (×10^3/𝜇L)	482.80 ± 86.51	470.70 ± 69.16	432.60 ± 84.13	401.40 ± 67.02	467.20 ± 37.77	425.60 ± 48.19
Total WBC (×10^3/𝜇L)	10.68 ± 3.72	8.92 ± 2.46	10.28 ± 3.75	8.53 ± 3.43	8.38 ± 2.11	8.88 ± 2.82
N (%)	21.00 ± 3.83	21.20 ± 3.49	21.10 ± 3.48	21.10 ± 3.48	21.80 ± 4.32	21.20 ± 3.03
L (%)	75.40 ± 3.98	75.80 ± 3.52	75.60 ± 2.91	75.30 ± 2.87	75.20 ± 4.02	75.20 ± 3.19
E (%)	1.30 ± 0.95	1.20 ± 0.79	1.10 ± 0.74	1.40 ± 0.70	0.80 ± 0.84	1.20 ± 0.84
M (%)	2.30 ±1.06	1.80 ± 0.79	2.20 ± 0.79	2.20 ± 0.92	2.20 ± 1.10	2.40 ± 1.14
B (%)	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
Pt (s)	14.90 ± 2.33	14.50 ± 2.37	14.60 ± 2.55	15.00 ± 2.62	15.00 ± 2.92	15.80 ± 2.86

∗P < 0.05 versus control group.
∗∗P < 0.01 versus control group.
#P < 0.05 versus recovery control group.